【レポートの概要(一部)】
1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
2. Introduction to Antibacterials and Antibacterial Drugs
2.1 Bacterial Infections
2.1.1 How Bacteria Cause Infections
2.1.2 Classification of Bacteria
2.1.3 Types of Bacterial Infection
2.1.4 Leading Causative Bacterium
2.1.5 Incidence and Mortality Profiles for Common Bacterial Infection
2.2 Treating Infections
2.2.1 The History of Antibacterial Drug Development
2.2.2 Mechanisms of Action
2.2.3 Leading Classes of Antibacterial Compounds
2.2.3.1 Cephalosporins
2.2.3.2 Penicillins
2.2.3.3 Carbapenems
2.2.3.4 Fluoroquinolones
2.2.3.5 Macrolides
2.3 Antibacterial Drugs Resistance
3. Antibacterial Drugs: World Market, 2014-2024
3.1 Antibacterials Revenues Plateau between 2009 and 2013
3.1.1 Antibacterial Drugs – Market Segmentation
3.2 Antibacterial Market Forecast, 2014-2024: Decline in Revenues for Fluoroquinolones
3.2.1 Drivers and Restraints in the Antibacterial Market, 2014-2024
3.2.2 Generic Erosion and Prescription Control will Limit Market Growth
3.2.3 Changes in Sector Market Shares, 2014-2024
3.3 Pfizer is the Clear Leader in the Antibacterial Drugs Market
3.3.1 Pfizer Usurped by Cubist as the Leading Antibacterial Drug Manufacturer – Company Revenue Forecasts 2014-2024
3.3.2 Fragmented Market to Fracture Further
3.3.3 Leading Firms without Leading R&D Pipelines
4. Cephalosporin Market Forecast, 2014-2024
4.1 Cephalosporin Market 2012-2013 – No Dominant Brands
4.2 Late-Stage Cephalosporins to Gain Market Share Between 2014 and 2024
4.3 Basilea, Cubist, and Forest Labs to Lead Cephalosporin Market Between 2014 and 2024
4.3.1 Drivers and Restraints in the Cephalosporins Market, 2014-2024
4.3.2 Cephalosporins Lack Market Exclusivity
4.3.3 Strong Pipeline for Novel Cephalosporins
4.4 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.4.1 Off Patent but not Forgotten
4.4.2 Declining Revenues Owing to Competition – Forecast 2014-2024
4.5 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.5.1 Continued Growth in the Emerging Markets, Revenue Forecast 2014-2024
4.6 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.6.1 Continued Decline in Revenue – Forecast 2014-2024
4.7 Meiact – A Broad Range Community Antibiotic
4.7.1 Minor Spectracef Sales in the US Leads to Pass the Product
4.7.2 Competition in Japan to Hinder Growth – Revenue Forecast 2014-2024
4.8 Flomox – Shionogi’s Third-Generation Cephalosporin
4.8.1 Patent Issues and Litigation
4.8.2 Genericisation and Safety to Restrict Sales – Forecast 2014-2024
4.9 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth-Generation Cephalosporins
4.9.1 Unmet Needs in Pneumonia to Drive Growth – Revenue Forecast 2014-2024
4.10 Zeftera (Ceftobiprole): Approved for Pneumonia in Europe
4.10.1 Future Sales Dictated by US Approval – Revenue Forecast 2014-2024
4.11 CXA-201 (Ceftrolozane-Tazobactam): The Next Blockbuster Antibacterial
4.11.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake – Revenue Forecast 2014-2024
4.12 CAZ-AVI (Ceftazidime-Avibactam): Forest Labs to Enter the Market on Phase II Data
4.12.1 Competition from CXA-201 to Limit Sales – Forecast 2014-2024
5. Penicillin Market Forecast, 2014-2024
5.1 Generics and Augmenting Dominate the Penicillins Market in 2012 and 2013
5.2 Augmentin to lose its Dominance over the Coming 10 Years – Market Shares for Penicillin Drugs, 2014-2024
5.3 Penicillin Antibacterials: Market Forecast 2014-2024
5.4 Drivers and Restraints on the Penicillin Market 2014-2024
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin Recalled in Asian and Middle Eastern Markets
5.5.2 Stable Revenues in Spite of Generic Competition
5.5.3 Revenue Forecast 2014-2024
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) – Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2014-2024
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Consistently Falling Revenues – Forecast 2014-2024
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue – Forecast 2014-2024
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2014-2024
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2014-2024
6. Fluoroquinolone Market Forecast, 2014-2024
6.1 The Fluoroquinolone Market 2012-2013
6.2 Changing Market Share for Fluoroquinolone Antibacterials 2014-2024
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2014-2024
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2014-2024
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2014-2024
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2014-2024
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2009-2012
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2014-2024
6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2014-2024
6.9.2 Cipro Revenue Forecast 2013-2023: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2014-2024
6.11 Delafloxacin
6.11.1 Revenue Forecast 2014-2024
7. Macrolide Market Forecast, 2014-2024
7.1 Macrolide Market in 2012-2013
7.2 Changing Market Share for Macrolides, 2014-2024
7.3 Macrolide Antibacterials: Market Forecast 2014-2024
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Revenue 2012-2013
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2014-2024
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2014-2024
7.7 Dalacin
7.7.1 Revenue Forecast 2014-2024
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2014-2024
7.9 Solit
7.9.1 Revenue Forecast 2014-2024
8. Carbapenem Market Forecast, 2014-2024
8.1 Carbapenem Market 2012-2013
8.2 Changing Market Share for Carbapenems, 2014-2024
8.3 Carbapenem Market Forecast, 2014-2024
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and ?-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2014-2024
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2014-2024
8.7 Invanz
8.7.1 Revenue Forecast 2014-2024
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2014-2024
9. Other Antibiotic Drugs: Forecast, 2014-2024
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2014-2024
9.3 Other Antibacterials: Market Forecast, 2014-2024
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2023
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2014-2024
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2017, Revenue Forecast 2014-2024
9.7 Tygacil – A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Safer Novel Therapies Restricts Growth, Revenue Forecast 2014-2024
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2014-2024
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2014-2024
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US – Revenue Forecast 2014-2024
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Revenue Forecast 2014-2024
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2014-2024
9.13 Oritavancin – An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share, Revenue Forecast 2014-2024
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2014-2024
9.15 Surotomycin – Cubist’s Second Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2014-2024
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2014-2024
10. The Leading National Markets, 2014-2024
10.1 The US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2014-2024
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2013
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rate in the UK, US, and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – Massive Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
10.5 Antibacterial Drug Consumption by Nation, 2013
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Minor National Markets
10.6 The Antibacterials Market in the US
10.6.1 The Continued Dominance of the US Market
10.7 The European Union the Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2014-2024
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italians Continue to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 The Rising Use of Antibacterials Drugs Within the UK
10.7.7 Spanish Antibacterial Market to Grow Between 2018 and 2024
10.8 Japan – Still the Third Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2014-2024
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Government Controls Subdue Recent Growth – Market Forecast 2014-2024
10.12 Indian Market to Expand by 50% Over the Coming Decade
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2014-2024
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia, TB Explosion to Drive Growth – Forecast 2014-2024
11. The Antibacterial Drug R&D Pipeline in 2014
11.1 Gram-Positive vs. Gram-Negative
11.2 A Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Candidates Treatments
11.3.1 Ceftolozane-Tazobactam – Future Gram-Negative Blockbuster
11.3.2 Ceftazidime-Avibactam – Skipping Phase III Trials
11.3.3 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.4 Tedizolid – More Potent Than Zyvox with Fewer Doses?
11.3.5 Oritavancin – Differentiated by Dosing
11.3.6 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.7 Dalbavancin – A Pharmacoeconomic Proposition
11.3.8 Solithromycin – A Fluroketolide Without the Side-Effects
11.3.9 Finafloxacin – A Second pH Activated Fluoroquinolone with Broad Spectrum Activity
11.3.10 Eravacyline – Treating Gram-Negative cUTIs and cIAIs
11.3.11 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.12 Cadazolid: Largest PIII C. Difficile Trial
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Avarofloxacin is Still Waiting for a Partner
11.4.3 MK-7655 and Invanz – A Novel ?-Lactamase Combination
11.4.4 Omadacycline – Another Phase III Ready Partnership
11.4.5 Radezolid – On Melinta’s Back-Burner for Now
11.4.6 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.7 Sutezolid – Sequella Looking to Combine TB Treatments
11.4.8 Taksta (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.4.9 TD-1792 – A Russian Antibacterial
11.4.10 Brilacidin – A Novel Peptide Antibacterial Agent
11.4.11 POL7080 – Polyphor and Roche in Multi-Million Dollar Deal
11.4.12 BC-3781- Unique Mechanism of Action at 23S?
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Cystic Fibrosis? Not Anymore
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 – Early Stage mAb to S. Aureus
12. Qualitative Analysis of the Antibacterials Market, 2014
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities, and Threats within the Antibacterial Drug Market
12.2 STEP Analysis: Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand will Remain Strong
12.4 High Prevalence of Infection Worldwide
12.5 Worldwide Demand for Antibacterials Drugs
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Areas
12.7 Cutting Into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Poor Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates – Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development
13. Research Interviews from Our Survey
13.1 Interview with Dr Vu Truong, Founder & CSO, Aridis Pharmaceuticals, United States
13.1.1 Opportunities for Antibacterial Monoclonal Antibodies
13.1.2 Positioning Monoclonal Antibacterials in the Clinic
13.1.3 Differentiating Factor for Biological Antibacterials
13.1.4 Hazard Pitfalls in Clinical Development
13.1.5 Trends in Antibacterial Drug Market – Novel Targets Rewarded
13.1.6 The Commercial Hazard of Acute Therapeutics
13.1.7 Progress from Government Incentives, But More to Come on the Manufacturing Side
13.1.8 Bacteriophages, Potentially Innovative Therapeutics
13.2 Interview with Lyn Baranowski and Sue Cammarata, Melinta Therapeutics, United States
13.2.1 Opportunities in Treating Skin Infections and Gonorrhoea
13.2.2 Superior Effect in Overweight Populations
13.2.3 Focussing on the Domestic US Market
13.2.4 Anionic Activity Opens up Possibilities in treating cUTIs and cIAIs
13.2.5 Superiority Means Uptake Won’t be Restricted
13.2.6 Clear Regulatory Guidance Clears Paths to Development
13.3 Interview with Tetraphase Pharmaceuticals
14. Antibacterial Drugs Market to 2024: Conclusions
14.1 Three Blockbuster Antibacterials in 2013, Leading Brands of 2013
14.2 The Leading Branded Antibacterial Drugs in 2024
14.3 Signs of Life in the Antibacterial Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development
【レポート販売概要】
■ タイトル:世界の抗菌薬市場(2014-2024)■ 英文:Antibacterial Drugs: World Industry and Market Prospects 2014-2024
■ 発行日:2014年3月
■ 調査会社:visiongain
■ 商品コード:Visiongain-4052642
■ 調査対象地域:グローバル
- 窒化ガリウム(GaN)半導体デバイスの世界市場予測(~2023年):オプトセミコンダクター、パワーセミコンダクター、RFセミコンダクターThe gallium nitride semiconductor device market is expected to reach USD 22.47 Billion by 2023 from USD 16.50 Billion in 2016, at a CAGR of 4.6% between 2017 and 2023. The major factors driving the growth of the gallium nitride semiconductor device market include the vast addressable market for gallium nitride in consumer electronics and automotive, wide bandgap property of gallium nitride materia …
- ディスポーザブル医療機器用センサーの世界市場:バイオセンサー、イメージセンサー、加速度センサー、圧力センサー、温度センサーThe global market is estimated to reach USD 5,936 Million by 2020, growing at a CAGR of 10.3% during the forecast period. The disposable medical device sensors market is primarily driven by the continuously increasing healthcare expenditure, increasing incidence of healthcare acquired infections, high prevalence of diabetes and other cardiovascular diseases and growing pressure on healthcare organ …
- サービスとしての調達の世界市場予測(~2024年)The growing demand to improve procurement operations and need to reduce the cost associated with procurement among the organizations to drive the market growth The global procurement as a service market size is expected to grow from USD 5.4 billion in 2019 to USD 7.8 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 7.6% during the forecast period. The procurement as a service market is …
- フィジカルIPの世界市場2017-2021About Physical Intellectual PropertyPhysical IPs are referred as the design of building blocks used in the development of SoCs. Physical IP, which includes analog and mixed signal, memory cells, wired interface, wireless interface, and physical library accounted for a revenue share of 32.05% in the global semiconductor IP market. Technavio’s analysts forecast the global physical intellectual prope …
- マイクロフォンの世界市場2016-2020About Microphones In a microphone, sound waves connect with the diaphragm, which is placed next to an electrically charged plate, causing it to vibrate. As it vibrates, it changes the electric field between the diaphragm and the plate. This generates an electrical signal that corresponds to the sound. When exposed to high volume, the electronics in a condenser microphone can overload, which poses …
- 世界の香料(香水)製品市場動向:ニュース・イベント(2014年5月)Synopsis The report provides a review of the latest news and key events in the global fragrances market during May 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global fragrances market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global f …
- グローバル軍事航空市場(2014-2024):競争環境及び戦略的インサイトSynopsis This report shows the leading Military Aviation market segments in various regions across the world. Details of top companies active across the global Military Aviation market are provided, together with market size and forecast 2014-2024 for the main players across those areas. Summary The report provides a detailed analysis of the competitive landscape of the Military Aviation market. I …
- 油流出管理の世界市場分析:技術別(油流出前(ダブルハル、パイプライン漏れ検出、ブローアウト防止装置)油流出後)、対応方法別(機械的な封じ込めと回収(封じ込めブーム(ハードブーム、吸着剤ブーム、火災ブーム)、スキマー(ウィアースキマー、親油性スキマー、非親油性スキマー)、吸着剤、化学回復(ゲル化剤、分散剤)、生物学的回収、物理的回収)、用途別、セグメント予測The global oil spill management market size is expected to reach USD 125.62 billion by 2022, according to a new report by Grand View Research, Inc. Increasing oil spill incidents since the past five years coupled with stringent safety and environmental regulations are expected to remain key driving factor for global oil spill management market. In addition, increasing seaborne and pipeline transpo …
- 低温装置の世界市場2016-2020About Cryogenic TechnologyCryogenic technology involves production, maintenance, and application of low temperatures below 150⁰F. This technology has increased its scope of application from cold storage to core processes in various end-user industries. The petrochemical and chemical industry holds a major revenue share in the global cryogenic equipment market. The applications of cryogenic equipme …
- 第2世代の燃料電池分析In the last couple of years, biofuels have become a popular source of renewable energy around the world. Biofuels have also emerged as the most cost effective renewable energy resource. The availability of biofuels is not an issue and many countries have put in place various regulations and tax incentives supporting the development of the biofuels industry. While earlier the industry witnessed a w …
- メキシコの移動補助・運搬機器市場見通し(~2021)Mexico Mobility Aids and Transportation Equipment Market Outlook to 2021 Summary GlobalData’s new report, "Mexico Mobility Aids and Transportation Equipment Market Outlook to 2021", provides key market data on the Mexico Mobility Aids and Transportation Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market se …
- 欧州主要国の手術室用装置市場見通し(~2021)EU5 Operating Room Equipment Market Outlook to 2021 Summary GlobalData’s new report, "EU5 Operating Room Equipment Market Outlook to 2021", provides key market data on the EU5 Operating Room Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Operating Room Tables, Operating Room Lights and Surgi …
- 静脈照射器の世界市場:透過照明、近赤外線照明、超音波技術The vein illuminator market is expected to grow at a CAGR of 32.41% between 2016 and 2022. The growth of the market is expected to be driven by the growing aging population, pediatric applications and growing demand for high patient satisfaction level. Out of the major end-user industries, market for hospitals is expected to grow at a high CAGR between 2016 and 2022 owing to the demand for technol …
- 屋外無線LANの世界市場2015-2019About outdoor Wi-Fi Wi-Fi networks emerged as one of the most popular wireless network protocol of 21st century. It is widely used both in indoor as well as outdoor environment to power public hotspot networks, home networks, and business local area networks. Indoor environment includes mainly households, whereas outdoor environment includes schools, colleges, stadiums, transportation hub, parking …
- 自動車シートベルト・プリテンショナーの世界市場About Automotive Seatbelt Pre-tensioners Seatbelt pre-tensioner, a passive safety system, is activated when an installed sensor detect a rapid deceleration during an accident. It is used to manage the occupant's energy in a crash by pulling the driver and front-seat passenger firmly into their seats, thereby reducing the occupant's load in a violent crash. Automotive seatbelt pre-tensioners tighte …